Antibody Engineering and Modification: Maximizing Therapeutic and Diagnostic Utility

I. Antibody Engineering

By operating at the DNA level, we can fundamentally alter the functional properties of an antibody.

1. Humanization and Fully Human Antibodies

Early therapeutic antibodies were predominantly derived from mice (murine antibodies). However, upon administration into the human body, these murine antibodies are recognized as "non-self" by the human immune system, triggering immune responses that lead to rapid clearance of the antibody — or even hypersensitivity reactions — significantly compromising therapeutic efficacy. Through antibody humanization, the complementarity-determining regions (CDRs) of a murine antibody are grafted onto a human antibody framework. More advancedly, through phage display technology or transgenic mouse platforms, fully human antibodies can be directly obtained. These antibodies elicit virtually no immune rejection, thereby markedly improving drug safety and long-term therapeutic efficacy.

2. Antibody Fragments and Miniaturization

Intact IgG antibodies possess a large molecular structure, resulting in limited tissue penetration. By expressing specific functional fragments — such as Fab fragments, single-chain variable fragments (scFv), or nanobodies (VHH) — tissue penetration capacity is significantly enhanced, and the accelerated clearance rate provides distinct advantages in tumor imaging and radioimmunotherapy.

3. Antibody-Drug Conjugates (ADCs)

ADCs represent the quintessential integration of antibody engineering and chemical modification. An ADC comprises three components: an antibody, a linker, and a cytotoxic payload. The antibody serves primarily to achieve precise recognition and binding to a specific antigen; upon binding, the entire ADC conjugate is internalized into the target cell via receptor-mediated endocytosis, enabling selective killing of tumor cells.

II. Antibody Modification

Antibody modification involves chemical modification at the protein level.

(1) PEGylation

PEG (polyethylene glycol) is a non-toxic, non-immunogenic, and highly hydrophilic polymeric compound. The primary objective of PEGylation is to extend the serum half-life of the antibody. By forming a hydrophilic protective shield on the antibody surface, PEGylation slows the rate of antibody clearance from the bloodstream, improves solubility, enhances formulation stability, and can mask surface epitopes that might be recognized by the immune system, thereby further reducing immunogenicity. PEGylation is widely employed in the development of long-acting therapeutics; numerous protein and peptide drugs have achieved once-weekly or even biweekly dosing regimens through PEGylation.

(2) Fluorescent and Quencher Group Labeling

Commonly used labels include:

FITC (Fluorescein isothiocyanate): Emits green fluorescence. As one of the pioneering fluorophores in flow cytometry, it is cost-effective and widely applied.

Cy5/Cy7 (Cyanine dyes): Emit far-red / near-infrared (NIR) fluorescence. Biological tissues exhibit minimal autofluorescence in this spectral range, and light penetration depth is enhanced; therefore, Cy5/Cy7-labeled antibodies are particularly suited for in vivo imaging and deep tissue imaging, enabling non-invasive tracking of tumors, inflammatory lesions, and other pathological sites.

Quencher groups: Such as BHQ (Black Hole Quencher) and Dabcyl. These molecules do not emit fluorescence themselves but effectively absorb or transfer energy from fluorescent groups at specific wavelengths, rendering their fluorescence undetectable.

In flow cytometry, multiple fluorescently labeled antibodies are used simultaneously, enabling rapid, multiparametric quantitative analysis of heterogeneous cell populations (e.g., peripheral blood). When Cy5- or Cy7-labeled antibodies are administered to animal models, real-time in vivo tracking of antibody biodistribution is achieved. Fluorescent and quencher groups are commonly employed in the preparation of molecular probes and biosensors.

Company Description

Tech-Bio (Tianjin) Co., Ltd. has established a comprehensive targeted antibody drug discovery platform based on phage display and yeast display technologies, providing high-quality therapeutic monoclonal antibody development services across various antibody formats — including scFv, VHH, and Fab — to scientists worldwide. The company is also capable of developing functional and structurally characterized antibodies (including but not limited to neutralizing antibodies, conformation-specific antibodies, and cross-reactive antibodies). Additionally, Tech-Bio offers complementary downstream services including antibody expression and validation, antibody humanization design and validation, antibody affinity maturation, and CAR-T candidate sequence design, comprehensively meeting the diverse needs of clients in therapeutic antibody development.

Previous:Bispecific Antibodies (bsAbs): Mechanisms of Action Explained Next:None!